Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New paper published in Nature Communications from researchers in Respiratory Medicine Unit, NDM Experimental Medicine'

Mucosal-associated invariant T (MAIT) cells are a recently-discovered type of white blood cell which are believed to play an important role in protecting humans, and many other mammals, from infections. They are able to detect minute quantities of vitamin metabolites produced in cells infected with bacteria and yeasts, but so far they have not been shown to protect against a major human disease. In work undertaken at the University of Melbourne, and published in the journal Nature Communications, the team and I have shown that in humans and animals MAIT cells can respond to two strains of Legionella: the bacterium which causes the very serious lung infection, Legionnaire’s disease. Importantly we showed in mice that having MAIT cells improves the chances of survival. For the first time we also showed that this protection against disease could be improved by activating these cells with vitamin metabolites. This could be an exciting new approach to protecting people against serious lung infections.

Find out more (Nature Communications)

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Discovery of gene involved in chronic pain creates new treatment target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.

Oxford's largest ever study into Varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications establishes for the first time, a critical genetic risk score to predict the likelihood of patients suffering with Varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Biological processes of ageing is key to improving later life health

Improvements in health care, sanitation, and diet over last 100 years have significantly increased life expectancy. However, this increase in how long we can expect to live has not been accompanied by a similar increase in healthy life expectancy, defined as the time spent free of major illness or disease.